Interestingly, despite the substantial increase in tumor size detected by our mice model following SMARCB1 genetic silencing, lower SMARCB1 expression did not appear to impact the PFI of non-TKI-treated patients. This evidence concerns the gene SMARCB1 and neoplasm.